On 10 September 2026, H WORLD-S (01179.HK) announced the pricing of RMB 3.35 billion senior unsecured notes, comprising 2.25% notes due 2031, offered to non-US persons offshore under Regulation S. The offering is expected to close on or around 16 September 2026, with net proceeds for general corporate purposes and the notes expected to be listed on the Hong Kong Stock Exchange.
On 9 September 2026, HUA LIEN INT'L (00969.HK) announced that Mr. Shi Zhu, the independent non-executive director suspended since April 2025 following the potential irregularities investigation at Ding Shi Capital (00804.HK), will resume his duties as independent non-executive director and his committee positions from 9 September 2026, after the Board and nomination committee concluded there are insufficient grounds to question his integrity, character or suitability.
On 9 September 2026, LEE'S PHARM (00950.HK) announced an exclusive license agreement with US-based 1cBio for OC-3, a preclinical-stage next-generation selective PARP1 inhibitor for homologous recombination repair-deficient cancers, covering development, manufacture and commercialization in Greater China and certain Southeast Asian countries. Lee's Pharmaceutical (Hong Kong) will be responsible for GLP safety studies and manufacturing.
On 9 September 2026, CHINA ENV TEC (00646.HK) announced the appointment of Mr. Shu Zhongwen as executive director and managing director, and Professor Geng Lin as independent non-executive director and member of the audit, remuneration and nomination committees, effective 9 September 2026.
On 9 September 2026, YIDU TECH (02158.HK) announced that its affiliate Yidu Cloud (Beijing) has won the bid for the Shanghai Pulmonary Hospital data platform localization upgrade project, with a total value of approximately RMB 3.57 million, as published on the National Public Resources Trading Platform (Shanghai).
On 9 September 2026, Shandong Boan Biotechnology Co., Ltd. (06955.HK) announced that it had entered into a supplementary agreement with Industrial Financial Leasing in respect of its finance lease agreement: after adjusting certain machinery and equipment items comprising the leased assets, the parties confirmed that the purchase price of RMB 75.00 million was determined with reference to the book value of the adjusted leased assets as of 31 August 2026 (approximately RMB 100.61 million), with the purchase price and the transaction's classification remaining unchanged.
On 9 September 2026, Minsheng Education Group Company Limited (01569.HK) announced receipt of a final HKIAC award dated 8 September 2026 ordering specific performance of the sale of a 49% interest in Lide International Education Group under a 2018 SPA at an exit price of RMB 2,180,735,576.50 plus costs and interest, with completion subject to resolution of share encumbrances; the company has sought to set aside the partial award before the Hong Kong High Court since July 2026.
On 9 September 2026, Jinxin Fertility Group Limited (01951.HK) announced in a voluntary announcement its proposal to develop a translational medicine platform focusing on women's health (initially targeting ovarian ageing and diminished ovarian reserve), leveraging its existing clinical and reproductive medicine capabilities; it has signed a research MOU with academician Professor Ji Weizhi and a framework agreement with a research animal resources partner, with the platform at an early stage and no material near-term impact expected.
On 9 September 2026, JNBY Design Limited (03306.HK) announced that independent non-executive director Mr. Lam Hiu Po will not seek re-election at the annual general meeting on 2 October 2026 and will retire as INED, audit committee chairman and remuneration committee member, with Mr. Wong Shun Tak to take over as audit committee chairman and remuneration committee member with effect from the conclusion of the AGM.
On 9 September 2026, Qingda Oriental Group Co., Ltd. (08115.HK) announced that the board lot size of its H shares would be changed from 4,000 to 500 shares with effect from 30 September 2026; based on the closing price of HKD 5.10, the market value per lot would fall from approximately HKD 20,400 to HKD 2,550, which the company said would lower the investment threshold, facilitate trading and improve liquidity.
On 9 September 2026, Shen Tong Robot Education Group Limited (08206.HK) announced the appointment of Grand Finance Capital Limited as independent financial adviser, upon approval of the independent board committee, to advise independent shareholders on the debt capitalisation, subscription agreement and whitewash waiver; the company's shares have been suspended since 14 October 2025 and remain suspended pending fulfilment of the resumption guidance.
On 9 September 2026, Baiying Holdings Group Limited (08525.HK) announced that it had fulfilled all GEM resumption guidance (demonstrating compliance with Rule 17.26 and informing the market of material information) and applied for resumption of trading from 10 September 2026; the group operates finance leasing, financial information services (SaaS system) and paper products trading, and has obtained RMB 400 million of bank facilities without controlling shareholder guarantees.
On 9 September 2026, Wuhan YZY Biopharma Co., Ltd. (02496.HK) announced a proposed allotment of 35,592,400 domestic shares to three director-subscribers at RMB 2.43 per share for net proceeds of approximately RMB 83 million, with 90% to repay bank borrowings; as the subscribers' and concert parties' aggregate stake would rise to approximately 52.17%, a whitewash waiver is being sought, and trading in the H shares is scheduled to resume on 10 September 2026.
On 9 September 2026, Kunming Dianchi Water Treatment Co., Ltd. (03768.HK) disclosed in an inside information announcement that shares held by controlling shareholder Kunming Dianchi Investment in the company remain under judicial freeze for three years (9 September 2026 to 8 September 2029) within RMB 123,530,242.28, following an assistance enforcement notice from the Panlong District People's Court; Kunming Dianchi Investment holds 37.79% of the company's domestic shares, all subject to pledges and/or freezes, and the company said its normal operations are unaffected.
On 9 September 2026, Guangdong ADWAY Construction (Group) Holdings Company Limited (06189.HK) announced the appointment of executive director Mr. Liu Zhenyu as chief executive officer with effect from 7 September 2026; Mr. Liu, aged 53, joined the group on 27 August 2026 and previously served in management roles at China Construction Second Engineering Bureau and several other companies, under a three-year service agreement with annual remuneration of RMB 80,000 (before tax).
On 9 September 2026, China Energy Engineering Corporation Limited (03996.HK) announced that its subsidiary Northwest Electric Power Design Institute had won the EPC contract for the Phase II of the Shaanxi Investment Zhaoshipan Power Plant (2×1000MW units) with a contract value of RMB 6.44 billion, covering two 1,000 MW ultra-supercritical coal-fired units and environmental facilities with a construction period of about 31 months; the contract has not yet been formally signed.
